Related Experiment Video
Updated: Jun 29, 2025
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
Caregiver perspectives on patient-focused drug development for Phelan-McDermid syndrome
Luciana Gizzo1, Geraldine Bliss2, Chrystal Palaty3
1University of New England College of Osteopathic Medicine, Biddeford, ME, USA.
Insights
Caregivers of individuals with Phelan-McDermid syndrome (PMS) shared their priorities for treatment with the FDA. Key goals include enhancing cognitive function, communication, independence, and reducing regression to improve quality of life.
Area of Science:
- Neurodevelopmental disorders
- Genetics
- Rare diseases
Background:
- Phelan-McDermid syndrome (PMS) is a neurodevelopmental disorder resulting from SHANK3 gene haploinsufficiency.
- The condition significantly impacts patients' quality of life due to its severe clinical manifestations.
Purpose of the Study:
- To summarize findings from an Externally Led Patient-Focused Drug Development (EL-PFDD) meeting.
- To convey the impact of PMS symptoms on patients' lives and treatment needs to the Food and Drug Administration (FDA).
- To provide a clinical perspective on caregiver priorities to inform future drug development and research.
Main Methods:
- An EL-PFDD meeting was convened for families affected by PMS.
- Caregivers shared their experiences and priorities regarding symptom management and treatment goals.
- A Voice of the Patient report was generated to summarize meeting outcomes.
Main Results:
- Caregivers emphasized the need for treatments that improve quality of life for individuals with PMS.
- Key priorities include enhancing cognitive function and communication abilities.
- Increased independence and a reduced risk of regression were also highlighted as critical goals.
Conclusions:
- Caregiver priorities center on improving overall quality of life for loved ones with PMS.
- Future therapeutic development should focus on cognitive, communication, and independence aspects.
- Understanding these caregiver-defined priorities is crucial for guiding the FDA and scientific community in developing effective PMS treatments.
Background:
Phelan-McDermid syndrome (PMS) is a neurodevelopmental disorder caused by SHANK3 haploinsufficiency with clinical manifestations that can be devastating and profoundly affect quality of life.
Results:
The Externally Led Patient-Focused Drug Development (EL-PFDD) meeting was an opportunity for families affected by PMS to share with the Food and Drug Administration (FDA) how symptoms impact their lives and how treatments could be most meaningful. The Voice of the Patient report serves as a summary of this meeting to influence upcoming drug development and clinical trials. The purpose of this report is to provide a clinical perspective on the results of the EL-PFDD meeting to amplify the voice of these caregivers to the scientific community.
Conclusions:
Caregivers prioritize an improved quality of life for their loved ones characterized by improved cognitive function, improved communication, increased independence, and reduced risk of regression. With these caregiver priorities in mind, this report provides the FDA and the scientific community with a clear understanding of which aspects of PMS should influence the development of future therapeutics.
Related Concept Videos
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:28Drug Therapy
Antianxiety Medications
01:28Preclinical Development: Overview
01:11Clinical Trials: Overview
01:26Drug Discovery: Overview
01:21EPS and iPS Cells in Disease Research